Current developments in the management of locally advanced esophageal cancer

Current Oncology Reports

Volumn 14, Issue 4, 2012, Pages 342-349

  McNamara, Michael J ^a   Adelstein, David J ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Cetuximab; Chemoradiation; Locally advanced esophageal cancer; Oxaliplatin; PET; Staging; Trastuzumab

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ETOPOSIDE; FLUORODEOXYGLUCOSE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; OXALIPLATIN; PACLITAXEL; TRASTUZUMAB;

ADENOSARCOMA; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; HUMAN; INDUCTION CHEMOTHERAPY; LOW DRUG DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STOMACH ADENOCARCINOMA;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; HUMANS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84865644690     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-012-0239-7     Document Type: Article

References (45)

1. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310-7. (Pubitemid 46218723)
2. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: Long term follow-up of a prospective randomized trial (RTOG 85-01). JAMA. 1999;281:1623-7. (Pubitemid 29211772)
3. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus; FFCD 9102. J Clin Oncol. 2007;25:1160-7.
4. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Eng J Med. 1996;335:462-7. (Pubitemid 26269945)
5. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Eng J Med. 2001;345:725-30.
6. Allum WH, Stenning SP, Bancewicz J, et al. Long term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062-7.
7. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Eng J Med. 2006;335:11-20.
8. • Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated meta-analysis. Lancet Oncol. 2011;12:681-92. This is a large meta-analysis which provides strong evidence for a survival benefit from preoperative chemotherapy and chemoradiotherapy as compared to surgery alone in patients with esophageal cancer. The benefits of these treatment modalities are further analyzed by tumor histology.
9. • Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851-6. This randomized phase III trial which focused exclusively on patients with adenocarcinoma of the proximal stomach, gastroesophageal junction, and distal esophagus, demonstrated significantly improved pathologic complete response rates with preoperative concurrent chemoradiation compared to preoperative chemotherapy. While there appears to be a trend favoring chemoradiotherapy, the improvements in survival outcomes were not statistically significant.
10. Burmeister BH, Thomas JM, Burmeister EA, et al. Is concurrent radiation therapy required in patients receiving chemotherapy for adenocarcinoma of the oesophagus? A randomized phase II trial. Eur J Cancer. 2011;47:354-60.
11. Gaast AV, Van Hagen P, Hulshof D, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. J Clin Oncol. 2010;28:15s (suppl; abstr 4004).
12. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Eng J Med. 2008;358:36-46.
13. • Montagnani F, Turrisi G, Marinozzi C, et al. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: A systematic review and meta-analysis. Gastric Cancer. 2011;14:50-5. This review suggests that oxaliplatin provides greater efficacy with less toxicity than cisplatin in patients with metastatic gastric and gastroesophageal junction adenocarcinoma.
14. • Conroy T, Yataghene Y, Etienne PL, et al. Phase II randomized trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in esophageal cancer. Br J Cancer. 2010;103:1349-55. This phase II study suggests that concurrent chemoradiotherapy with FOLFOX4 provides a similar degree of benefit as the combination of cisplatin and 5FU.
15. Leichman LP, Goldman BH, Bohanes PO, et al. S0356: A phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol. 2011;29:4555-60.
16. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC cancer staging manual: Esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17:1721-4.
17. Rice TW, Rusch VW, Ishwaran H, et al. Cancer of the esophagus and esophagogastric junction: Data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer. 2010;116:3763-73.
18. Peyre CG, Hagen JA, DeMeester SR, et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: A multinational study on the significance of the number of involved lymph nodes. Ann Surg. 2008;248:979-85.
19. Kelty CJ, Kennedy CW, Falk GL. Ratio of metastatic lymph nodes to total number of nodes resected is prognostic for survival in esophageal carcinoma. J Thorac Oncol. 2010;5:1467-71.
20. Meyers BF, Downey RJ, Decker PA, et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: Results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovascular Surg. 2007;133:738-45.
21. Levine EA, Farmer MR, Clark P, et al. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography ([18] F FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006;243:472-8.
22. • Monjazeb AM, Riedlinger G, Aklilu M, et al. Outcomes of patients with esophageal cancer staged with [18F] Fluorodeoxyglucose positron emission tomography (FDG-PET): Can post chemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol. 2010;28:4714-21. This retrospective study suggests that patients with a negative FDG-PET after definitive concurrent chemoradiotherapy have improved survival compared with patients who have residual FDG uptake.
23. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692-8. (Pubitemid 46646244)
24. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesphagogastric junction: The MUNICON phase II trial. Lancet Oncol. 2007;8:797-805. (Pubitemid 47308659)
25. • Meyer zum Buschenfelde C, Herrmann K, Schuster T, et al. F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: The MUNICON II trial. J Nucl Med. 2011;52:1189-96. This is a phase II study that employs salvage preoperative chemoradiotherapy in patients who do not demonstrate an early response by FDG-PET to induction chemotherapy.
26. Wilkinson NW, Black JD, Roukhadze E, et al. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg. 2004;8:448-53. (Pubitemid 38561209)
27. Wang KL, Wu T, In SC, et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: Association with poor outcome. Cancer. 2007;109:658-67. (Pubitemid 46233226)
28. Gibault L, Metges JP, Conan-Charlet V, et al. Diffuse EGFR staining is associated with a reduced overall survival in locally advanced oesphageal squamous cell cancer. Br J Cancer. 2005;93:107-15. (Pubitemid 41076258)
29. Hanawa M, Suzuki S, Dobashi Y, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer. 2005;118:1173-80.
30. Adelstein DJ, Rodriguez CP, Rybicki LA, et al. A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction. Invest New Drugs 2011, [Epub ahead of print].
31. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol. 2006;24:4922-6.
32. Ilson DH, Kelsen D, Shah M, et al. A phase II trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer. 2011;117:1409-14.
33. Rodriguez CP, Adelstein DJ, Rice TW, et al. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol. 2010;5:229-35.
34. Wainberg ZA, Lin L-S, DiCarlo B, et al. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer. 2011;105:760-5.
35. Gold PJ, Goldman B, Iqbal S, et al. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: A phase II southwest oncology group study (S0415). J Thorac Oncol. 2010;5:1472-6.
36. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-flourouracil versus cisplatin-5-flourouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: A randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009;20:1667-73.
37. Ruhstaller T, Pless M, Dietrich D, et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase Ib/II trial (SAKK75/06). J Clin Oncol. 2011;29:626-31.
38. De Vita F, Orditura M, Martinelli E, et al. A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. Br J Cancer. 2011;104:427-32.
39. Phillips BE, Tubbs RR, Rice TW, et al. Clinicopathologic features and treatment outcomes of patients (pts) with HER2-positive (pos) adenocarcinomas (ACA) of the esophagus (E) and gastroesophageal junction (GEJ). J Clin Oncol 2011;29 (suppl; abstr 4046).
40. Schoppmann SF, Jesch B, Friedrich J, et al. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol. 2010;34:1868-73.
41. Langer R, Rauser S, Feith M, et al. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: Summary of a revised immunohistochemical evaluation system, bright field double in situ hybridization and fluorescence in situ hybridization. Mod Pathol. 2011;24:908-16.
42. •• Bang Y, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): A phase 3, open-label, randomized controlled trial. Lancet. 2010;376:687-97. This study demonstrates that the addition of trastuzumab to chemotherapy provides a survival advantage for patients with metastatic gastric and gastroesophageal adenocarcinoma who express HER2.
43. Safran H, DiPetrillo T, Akerman P, et al. PhaseI/II study of trastuzumab, paclitaxel, cisplatin, and radiation for locally advanced, Her2 overexpressing, esophageal adenocarcinoma. Int J Radiation Oncology Biol Phys. 2007;67:405-9. (Pubitemid 46108313)
44. Pinto C, Di Fabio F, Barone C, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer. 2009;101:1261-8.
45. Chan JA, Blaszkowsky LS, Enzinger PC, et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol. 2011;22:1367-73.